1. Home
  2. VNDA

VNDA

Vanda Pharmaceuticals Inc.

Logo Vanda Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.

Founded: N/A Country:
United States
United States
Employees: N/A City: WASHINGTON
Market Cap: 286.0M IPO Year: 2006
Target Price: N/A AVG Volume (30 days): 2.3M
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 0.04 EPS Growth: -63.64
52 Week Low/High: $3.30 - $7.00 Next Earning Date: 05-01-2024
Revenue: $192,640,000 Revenue Growth: -24.27%
Revenue Growth (this year): 2.98% Revenue Growth (next year): 19.49%

Share on Social Networks: